Bicycle therapeutics reports third quarter 2022 financial results and provides corporate update

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today reported financial results for the third quarter ended september 30, 2022 and provided recent corporate updates.
BCYC Ratings Summary
BCYC Quant Ranking